Thymopentin

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Thymopentin
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Other namesL-arginyl-L-lysyl-L-α-aspartyl-L-valyl-L-tyrosine
ATC codePage Template:Plainlist/styles.css has no content.
Identifiers
  • (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-hydroxy-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC30H49N9O9
Molar mass679.776 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(O)cc1)C(C)C)CC(=O)O)CCCCN)[C@@H](N)CCC/N=C(\N)N
  • InChI=1S/C30H49N9O9/c1-16(2)24(28(46)38-22(29(47)48)14-17-8-10-18(40)11-9-17)39-27(45)21(15-23(41)42)37-26(44)20(7-3-4-12-31)36-25(43)19(32)6-5-13-35-30(33)34/h8-11,16,19-22,24,40H,3-7,12-15,31-32H2,1-2H3,(H,36,43)(H,37,44)(H,38,46)(H,39,45)(H,41,42)(H,47,48)(H4,33,34,35)/t19-,20-,21-,22-,24-/m0/s1 checkY
  • Key:PSWFFKRAVBDQEG-YGQNSOCVSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Thymopentin is a thymic polypeptide derivative which interacts with T cells and acts as an immunostimulant.[1][2][3][4] As such, it was used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in some patients for a brief time under specific treatments.[5][6][7] It has also been investigated more recently for applications in the treatment of rheumatoid arthritis,[8] and lung cancer.[9]

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Liu Z, Zheng X, Wang J, Wang E (December 2007). Egli M (ed.). "Molecular analysis of thymopentin binding to HLA-DR molecules". PLOS ONE. 2 (12) e1348. Bibcode:2007PLoSO...2.1348L. doi:10.1371/journal.pone.0001348. PMC 2137936. PMID 18159232. Open access icon
  2. ^ Page Module:Citation/CS1/styles.css has no content.Peng Y, Chen Z, Yu W, Zhou Q, Xu L, Mao FF, et al. (October 2008). "Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells". Cell Biology International. 32 (10): 1265–1271. doi:10.1016/j.cellbi.2008.07.011. PMID 18692582. S2CID 24144448.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Wen Z, Li H, Zhou C, Chen L, Zhang L, Chen Y, et al. (January 2024). "Thymopentin plays a key role in restoring the function of macrophages to alleviate the sepsis process". International Immunopharmacology. 126 111295. doi:10.1016/j.intimp.2023.111295. PMID 38048668.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Chen X, Ruan Y, Xie J, Huang X, Zhang C, Cui Y, et al. (September 2025). "Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study". BMC Nephrology. 26 (1) 538. doi:10.1186/s12882-025-04465-w. PMC 12481784. PMID 41023915.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (September 1983). "Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients". Lancet. 2 (8352): 735–736. doi:10.1016/S0140-6736(83)92271-7. PMID 6193382. S2CID 519367.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Clumeck N, van de Perre P, Mascart-Lemone F, Cran S, Bolla K, Duchateau J (1984). "Preliminary results on clinical and immunological effects of thymopentin in AIDS". International Journal of Clinical Pharmacology Research. 4 (6): 459–463. PMID 6398315.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchateau J, Bolla K (1985). "Thymopentin treatment in AIDS and pre-AIDS patients". Survey of Immunologic Research. 4 (Suppl 1): 58–62. doi:10.1007/BF02919057. PMID 3898293. S2CID 36555170.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Sundal E, Bertelletti D (October 1994). "Thymopentin treatment of rheumatoid arthritis". Arzneimittel-Forschung. 44 (10): 1145–1149. PMID 7818590.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Liu Y, Lu J (2023). "Mechanism and clinical application of thymosin in the treatment of lung cancer". Frontiers in Immunology. 14 1237978. doi:10.3389/fimmu.2023.1237978. PMC 10493777. PMID 37701432.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Thymopentin&oldid=4766060"